Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 48 of 95, showing 5 Applications out of 474 total, starting on record 236, ending on 240

# Protocol No Study Title Investigator(s) & Site(s)

236.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
View

237.

ECCT/20/06/03   CVIA078
    A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine   
Principal Investigator(s)
1. Nathanial Kelsey Copeland
Site(s) in Kenya
Kombewa Clinical Research Centre
 
View

238.

ECCT/20/06/02   EMPACTA Covid19 Study
    A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
AgaKhan University Hospital Nairobi
 
View

239.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Prof Walter Jaoko Godfrey Jaoko
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
View

240.

ECCT/20/05/03   A5381
    Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment   
Principal Investigator(s)
1. Victor Mudhune
Site(s) in Kenya
Kisumu Clinical Research Center
 
View